Som tidigare rapporterats har Hamlet BioPharma uppnått banbrytande forskningsresultat om Alpha1H, bolagets läkemedelskandidat mot urinblåsecancer. I s...
As previously reported, Hamlet BioPharma has achieved a groundbreaking scientific discovery related to Alpha1H, the company’s lead drug candidate for t...
Hamlet BioPharma utvald att presentera framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 vid American Association for Cancer Resea...
As previously announced Hamlet BioPharma invites you to our monthly investors’ meeting to
be held on the 23rd of April 2025, at 12:00.
Please click on...
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs
for cancer and infections, announces the publication of new sci...
Hamlet BioPharma, the pharmaceutical company, specializing in the development of drugs
for cancer and infections, announces the publication of new sci...
Hamlet BioPharma, the pharmaceutical company, specializing in the
development of drugs for cancer and infections, announces that Hamlet
BioPharma’s dr...
Som tidigare meddelats bjuder Hamlet BioPharma in till månatligt investerarmöte
onsdagen den 12 mars, 2025, klockan 12.00.
Klicka på länken nedan för ...
Vid extra bolagsstämma i Hamlet BioPharma AB (publ), org.nr 556568-8958, (”Hamlet
BioPharma” eller ”Bolaget”) idag den 11 mars 2025 fattades bland ann...
